EDAP Media Interview Highlights Prostate Cancer
September 01 2010 - 9:16AM
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, is pleased to announce that its Chief Financial
Officer, Eric Soyer, was interviewed yesterday by The Wall Street
Reporter. The interview provides a corporate overview of EDAP TMS
and highlights the new Focal Therapy trend in the urology community
to address prostate cancer. The interview also covers EDAP's market
expansion of Ablatherm-High Intensity Focused Ultrasound (HIFU)
into China and recent advancements with its Sonolith i-sys and
Sonolith i-move, for which the company has submitted a 510(k)
application for marketing clearance to the U.S. Food & Drug
Administration.
Mr. Soyer discussed the current major shift to a new paradigm in
the treatment of prostate cancer that is called "focal therapy" as
opposed to current radical treatments of the prostate. There is a
growing demand for less aggressive treatment options for prostate
cancer while preserving patient quality of life. Focal therapy,
which calls for a targeted, precise treatment and significantly
reduces the side effects or complications, has the potential to be
a perfect compromise. "This trend is a huge market opportunity for
therapeutic ultrasounds, which indeed offer a unique blend of
treatment accuracy, efficacy, and reduced morbidity. And we at
EDAP, as one of the leaders in HIFU want to take advantage of that
trend and leverage our prominent IP portfolio and technological
expertise in the field."
Mr. Soyer further noted EDAP's potential opportunities in the
lithotripsy space. EDAP's two state of the art technologies to
treat urinary stones, Sonolith i-move and Sonolith i-sys, have been
approved by European and Japanese officials respectively. In the
U.S., we recently submitted the application for 510(k) marketing
clearance to the FDA for the Sonolith i-move. Upon clearance, EDAP
will then be well positioned to address all U.S. lithotripsy market
segments.
The interview is available at www.wallstreetreporter.com
directly via the following link:
http://www.wallstreetreporter.com/2010/08/edap-nasdaq-edap-management-interview/.
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm, the most advanced
and clinically proven choice for high-intensity focused ultrasound
(HIFU) treatment of localized prostate cancer. HIFU treatment is
shown to be a minimally invasive and effective treatment option
with a low occurrence of side effects. Ablatherm-HIFU is generally
recommended for patients with localized prostate cancer (stages
T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy
treatment. Approved in Europe as a treatment for prostate cancer,
Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently
undergoing evaluation in a multicenter U.S. Phase II/III clinical
trial under an Investigational Device Exemption granted by the FDA.
The Company also is developing this technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also
produces and commercializes medical equipment for treatment of
urinary tract stones using extra-corporeal shockwave lithotripsy
(ESWL). For more information on the company, please visit
http://www.edap-tms.com, http://www.hifu-planet.com.
CONTACT: EDAP TMS SA
Investor Relations / Legal Affairs
Blandine Confort
+33 4 72 15 31 72
bconfort@edap-tms.com
The Ruth Group
Investors:
Eric Schwerdtfeger
646-536-7026
eschwerd@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024